Mr. Lalji began his career with Merck & Company. While at Merck, he led the infectious disease new product portfolio from the commercial perspective, with responsibility for products such as INVANZ, CANCIDAS and CRIXIVAN. While spearheading the marketing and launch for CRIXIVAN, a breakthrough treatment for HIV disease, Mr. Lalji led the ultimate discovery of the "triple cocktail," which today remains the cornerstone of HIV treatment.

Mr. Lalji subsequently undertook responsibility for driving the global franchise strategies for Merck's two leading areas: cholesterol reducers and hypertension/heart failure treatments. His final role during his ten-year tenure at Merck was as an executive leading the worldwide osteoporosis franchise and its main product, FOSAMAX.

Subsequent to Merck, Mr. Lalji worked at Sepracor, Inc. in Boston, Massachusetts, where he was Vice President of Business Strategy and New Product Commercialization. Mr. Lalji was the primary architect of LUNESTA for the treatment of insomnia at Sepracor.

In 2006, Mr. Lalji joined Cardiome Pharma Corp. in Vancouver, British Columbia as Senior Vice President of Commercial Affairs and an officer of the company. He played a pivotal role in driving Cardiome's $1 billion worldwide licensing agreement with Merck & Company for vernakalant oral and IV for the management of atrial fibrillation.

Mr. Lalji serves on the Board of Overseers of Harvard University's Beth Israel Deaconess Medical Center in Boston, Massachusetts, a leading academic teaching hospital. Additionally, he is on the Board of Methylation Sciences Incorporated, a company developing a lead asset for the treatment of depression. Mr. Lalji holds a Science Masters Degree in Health Policy and Management from Harvard University in Cambridge, MA. He also holds a BBA from Simon Fraser University in British Columbia, Canada.

Dr. Julia Levy has served in several key senior posts at QLT, including Chief Scientific Officer and Vice President as well as President and CEO from 1995 to February 2002. Dr. Levy has also been a Director of QLT since 1983. In December 2006, she retired from the Board to become the Director of Emerita and continues to be actively involved in QLT's Scientific Advisory Board. Under Dr. Levy's leadership, QLT recorded the strongest period of growth in company history and earned a reputation for achieving milestones, including FDA approval for Visudyne® therapy to treat age-related blindness in April 2000.

Following her doctorate degree in immunology from the University of London, Dr. Levy was awarded an Industrial Professorship in the Department of Microbiology from the University of British Columbia and is the recipient of several honorary degrees. A fellow of the Royal Society of Canada and former President of the Canadian Federation of Biological Sciences, Dr. Levy has earned numerous awards and honors, including an appointment as an Officer of the Order of Canada in 2001, Female Entrepreneur of the Year for International Business in 1998, Pacific Canada Entrepreneur of the Year in 2000, and the Future of Vision Award from the Foundation Fighting Blindness in 2001.

In 2002, Dr. Levy received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. Along with Dr. Gustav Huber of Novartis, she was presented with the 2003 Helen Keller Prize for Innovation in Eye Care. In her honor, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the British Columbia Biotechnology Association.

Mr. May currently oversees the direct management of over $100 million in assets. He has 25 years of experience in building multiple $100 million per year corporations while managing individual companies with over 300 employees each.

Mr. May provides expertise for the many industrial applications of Microbion's technologies and brings an expertise in building, managing,and orchestrating the successful sale of companies he has owned or been directly involved in running.

Mr. May spent 25 years advancing his impact on fisheries and commercialization of new fisheries technologies, which culminated in the sale of one of his primary fishery companies in 2008. He currently maintains ownership in Copper River Seafoods, where he has had the direct impact of advancing sales from $1 million in 1997 and is on track to exceed $100 million in sales in 2010.

He is both a pioneer in the fisheries world, and one of the most successful individuals in fisheries. Mr. May has built his fortunes on integrity and relationships, as well as perfecting complex business negotiations in his lifetime of successful business transactions.

Dr. Jason J. Harmon is co-founder of the Oncology Association of Naturopathic Physicians and a Board member (and Fellow) of the American Board of Naturopathic Oncology. He is a past member of the Board of Directors of the Alaska Cancer Research and Education Center, previously responsible for cancer research trials conducted in Alaska.

Dr. Harmon offers Microbion a wealth of clinical knowledge, a diverse international network, and experience in raising equity capital. As a native Alaskan, he is very aware of the significant opportunities for Microbion's technology to serve the unmet, health-related needs of rural Alaska populations, as well as the key industrial needs of Alaska's oil industry.

Some of his many accomplishments include:

• Leading naturopathic physician
• Co-founder of the Oncology Association of Naturopathic Physicians
• Board member (and Fellow) of the American Board of Naturopathic Oncology
• Board-certified in Naturopathic Oncology
• Former member of the Board of Directors of the Alaska Cancer Research and Education Center